Barriers to accrual and enrollment in brain tumor trials

Eudocia Q. Lee; Ugonma N. Chukwueke; Shawn L. Hervey-Jumper; John F. De Groot; Jose Pablo Leone; Terri S. Armstrong; Susan M. Chang; David Arons; Kathy Oliver; Kay Verble; Al Musella; Nicole Willmarth; Brian M. Alexander; Amanda Bates; Lisa Doherty; Evanthia Galanis; Sarah Gaffey; Thomas Halkin; Bret E. Friday; Maryam Fouladi; Nancy U. Lin; David Macdonald; Minesh P. Mehta; Marta Penas-Prado; Michael A. Vogelbaum; Solmaz Sahebjam; David Sandak; Martin Van Den Bent; Michael Weller; David A. Reardon; Patrick Y. Wen

doi:10.1093/neuonc/noz104

Barriers to accrual and enrollment in brain tumor trials

Eudocia Q. Lee, Ugonma N. Chukwueke, Shawn L. Hervey-Jumper, John F. De Groot, Jose Pablo Leone, Terri S. Armstrong, Susan M. Chang, David Arons, Kathy Oliver, Kay Verble, Al Musella, Nicole Willmarth, Brian M. Alexander, Amanda Bates, Lisa Doherty, Evanthia Galanis, Sarah Gaffey, Thomas Halkin, Bret E. Friday, Maryam FouladiNancy U. Lin, David Macdonald, Minesh P. Mehta, Marta Penas-Prado, Michael A. Vogelbaum, Solmaz Sahebjam, David Sandak, Martin Van Den Bent, Michael Weller, David A. Reardon, Patrick Y. Wen

Medical Oncology

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Many factors contribute to the poor survival of malignant brain tumor patients, some of which are not easily remedied. However, one contributor to the lack of progress that may be modifiable is poor clinical trial accrual. Surveys of brain tumor patients and neuro-oncology providers suggest that clinicians do a poor job of discussing clinical trials with patients and referring patients for clinical trials. Yet, data from the Cancer Action Network of the American Cancer Society suggest that most eligible oncology patients asked to enroll on a clinical trial will agree to do so. To this end, the Society for Neuro-Oncology (SNO) in collaboration with the Response Assessment in Neuro-Oncology (RANO) Working Group, patient advocacy groups, clinical trial cooperative groups, including the Adult Brain Tumor Consortium (ABTC), and other partners are working together with the intent to double clinical trial accrual over the next 5 years. Here we describe the factors contributing to poor clinical trial accrual in neuro-oncology and offer possible solutions.

Original language	English (US)
Pages (from-to)	1100-1117
Number of pages	18
Journal	Neuro-oncology
Volume	21
Issue number	9
DOIs	https://doi.org/10.1093/neuonc/noz104
State	Published - Sep 6 2019

Keywords

Brain tumors
Clinical trial accrual
Neuro-oncology

ASJC Scopus subject areas

Oncology
Clinical Neurology
Cancer Research

Access to Document

10.1093/neuonc/noz104

Cite this

Lee, E. Q., Chukwueke, U. N., Hervey-Jumper, S. L., De Groot, J. F., Leone, J. P., Armstrong, T. S., Chang, S. M., Arons, D., Oliver, K., Verble, K., Musella, A., Willmarth, N., Alexander, B. M., Bates, A., Doherty, L., Galanis, E., Gaffey, S., Halkin, T., Friday, B. E., ... Wen, P. Y. (2019). Barriers to accrual and enrollment in brain tumor trials. Neuro-oncology, 21(9), 1100-1117. https://doi.org/10.1093/neuonc/noz104

Lee, EQ, Chukwueke, UN, Hervey-Jumper, SL, De Groot, JF, Leone, JP, Armstrong, TS, Chang, SM, Arons, D, Oliver, K, Verble, K, Musella, A, Willmarth, N, Alexander, BM, Bates, A, Doherty, L, Galanis, E, Gaffey, S, Halkin, T, Friday, BE, Fouladi, M, Lin, NU, Macdonald, D, Mehta, MP, Penas-Prado, M, Vogelbaum, MA, Sahebjam, S, Sandak, D, Van Den Bent, M, Weller, M, Reardon, DA & Wen, PY 2019, 'Barriers to accrual and enrollment in brain tumor trials', Neuro-oncology, vol. 21, no. 9, pp. 1100-1117. https://doi.org/10.1093/neuonc/noz104

@article{fb41904200114ddc96eef98986b25ea4,

title = "Barriers to accrual and enrollment in brain tumor trials",

abstract = "Many factors contribute to the poor survival of malignant brain tumor patients, some of which are not easily remedied. However, one contributor to the lack of progress that may be modifiable is poor clinical trial accrual. Surveys of brain tumor patients and neuro-oncology providers suggest that clinicians do a poor job of discussing clinical trials with patients and referring patients for clinical trials. Yet, data from the Cancer Action Network of the American Cancer Society suggest that most eligible oncology patients asked to enroll on a clinical trial will agree to do so. To this end, the Society for Neuro-Oncology (SNO) in collaboration with the Response Assessment in Neuro-Oncology (RANO) Working Group, patient advocacy groups, clinical trial cooperative groups, including the Adult Brain Tumor Consortium (ABTC), and other partners are working together with the intent to double clinical trial accrual over the next 5 years. Here we describe the factors contributing to poor clinical trial accrual in neuro-oncology and offer possible solutions.",

keywords = "Brain tumors, Clinical trial accrual, Neuro-oncology",

author = "Lee, {Eudocia Q.} and Chukwueke, {Ugonma N.} and Hervey-Jumper, {Shawn L.} and {De Groot}, {John F.} and Leone, {Jose Pablo} and Armstrong, {Terri S.} and Chang, {Susan M.} and David Arons and Kathy Oliver and Kay Verble and Al Musella and Nicole Willmarth and Alexander, {Brian M.} and Amanda Bates and Lisa Doherty and Evanthia Galanis and Sarah Gaffey and Thomas Halkin and Friday, {Bret E.} and Maryam Fouladi and Lin, {Nancy U.} and David Macdonald and Mehta, {Minesh P.} and Marta Penas-Prado and Vogelbaum, {Michael A.} and Solmaz Sahebjam and David Sandak and {Van Den Bent}, Martin and Michael Weller and Reardon, {David A.} and Wen, {Patrick Y.}",

year = "2019",

month = sep,

day = "6",

doi = "10.1093/neuonc/noz104",

language = "English (US)",

volume = "21",

pages = "1100--1117",

journal = "Neuro-oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "9",

}

TY - JOUR

T1 - Barriers to accrual and enrollment in brain tumor trials

AU - Lee, Eudocia Q.

AU - Chukwueke, Ugonma N.

AU - Hervey-Jumper, Shawn L.

AU - De Groot, John F.

AU - Leone, Jose Pablo

AU - Armstrong, Terri S.

AU - Chang, Susan M.

AU - Arons, David

AU - Oliver, Kathy

AU - Verble, Kay

AU - Musella, Al

AU - Willmarth, Nicole

AU - Alexander, Brian M.

AU - Bates, Amanda

AU - Doherty, Lisa

AU - Galanis, Evanthia

AU - Gaffey, Sarah

AU - Halkin, Thomas

AU - Friday, Bret E.

AU - Fouladi, Maryam

AU - Lin, Nancy U.

AU - Macdonald, David

AU - Mehta, Minesh P.

AU - Penas-Prado, Marta

AU - Vogelbaum, Michael A.

AU - Sahebjam, Solmaz

AU - Sandak, David

AU - Van Den Bent, Martin

AU - Weller, Michael

AU - Reardon, David A.

AU - Wen, Patrick Y.

PY - 2019/9/6

Y1 - 2019/9/6

N2 - Many factors contribute to the poor survival of malignant brain tumor patients, some of which are not easily remedied. However, one contributor to the lack of progress that may be modifiable is poor clinical trial accrual. Surveys of brain tumor patients and neuro-oncology providers suggest that clinicians do a poor job of discussing clinical trials with patients and referring patients for clinical trials. Yet, data from the Cancer Action Network of the American Cancer Society suggest that most eligible oncology patients asked to enroll on a clinical trial will agree to do so. To this end, the Society for Neuro-Oncology (SNO) in collaboration with the Response Assessment in Neuro-Oncology (RANO) Working Group, patient advocacy groups, clinical trial cooperative groups, including the Adult Brain Tumor Consortium (ABTC), and other partners are working together with the intent to double clinical trial accrual over the next 5 years. Here we describe the factors contributing to poor clinical trial accrual in neuro-oncology and offer possible solutions.

AB - Many factors contribute to the poor survival of malignant brain tumor patients, some of which are not easily remedied. However, one contributor to the lack of progress that may be modifiable is poor clinical trial accrual. Surveys of brain tumor patients and neuro-oncology providers suggest that clinicians do a poor job of discussing clinical trials with patients and referring patients for clinical trials. Yet, data from the Cancer Action Network of the American Cancer Society suggest that most eligible oncology patients asked to enroll on a clinical trial will agree to do so. To this end, the Society for Neuro-Oncology (SNO) in collaboration with the Response Assessment in Neuro-Oncology (RANO) Working Group, patient advocacy groups, clinical trial cooperative groups, including the Adult Brain Tumor Consortium (ABTC), and other partners are working together with the intent to double clinical trial accrual over the next 5 years. Here we describe the factors contributing to poor clinical trial accrual in neuro-oncology and offer possible solutions.

KW - Brain tumors

KW - Clinical trial accrual

KW - Neuro-oncology

UR - http://www.scopus.com/inward/record.url?scp=85073415117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073415117&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noz104

DO - 10.1093/neuonc/noz104

M3 - Article

C2 - 31175826

AN - SCOPUS:85073415117

SN - 1522-8517

VL - 21

SP - 1100

EP - 1117

JO - Neuro-oncology

JF - Neuro-oncology

IS - 9

ER -

Barriers to accrual and enrollment in brain tumor trials

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this